Market by Product, Application, Industry Verticals, and Country | Forecast 2021-2028
As per Triton’s report, the CRISPR market in Europe is estimated to observe growth at a compound annual growth rate of 19.43% during the projected phase of 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries studied in this market comprise:
• The United Kingdom
• Spain
• Germany
• Italy
• France
• Russia
• Rest of Europe
In
the United Kingdom, the government aims to boost the research and
commercialization of gene-edited food and agriculture products. Moreover, the
government is seeking guidance on how DEFRA should reform existing regulations
governing organisms produced using genetic technologies. Furthermore, the
country has vastly resisted the commercialization of gene technologies in food
products, owing to safety and environmental concerns. Nevertheless, the rising
research and development of technologies will highlight the use of CRISPR in
the agriculture sector. Hence, these factors are likely to create new
opportunities for the CRISPR market.
On
the other hand, partnerships among leading companies are resulting in
innovation in CRISPR technologies across Germany. For instance, ERS Genomic
granted a startup company Vivlion a non-exclusive license to its CRISPR-Cas9
patent portfolio to improve gene-editing screening services. Additionally,
earlier, the EU science community put significant pressure on regulators to reform
the genetic engineering law. Therefore, such steps to develop CRISPR
technologies are widening the scope and growth of the CRISPR market within the
country.
Cellectis
Bioresearch SAS is a biopharmaceutical company that is engaged in developing
adoptive immunotherapies for cancer. In addition, it aims to create a new
generation of therapies based on engineered T-cells. Moreover, the company’s
product line includes UCART, off-the-shelf, allogeneic products that can be
industrialized and standardized with a regular pharmaceutical release. With
over 16 years of experience in genome engineering, the company is headquartered
in France.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
CRISPR MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON CRISPR MARKET
2.2. KEY
INSIGHTS
2.2.1. INDUSTRIAL
BIOTECH IS THE FASTEST GROWING INDUSTRY VERTICAL
2.2.2. REWRITING
OF GENETIC DISORDERS THROUGH GENOME SURGERY
2.2.3. INCREASING
USAGE OF PROSPECTIVE APPLICATIONS OF CRISPR TECHNOLOGY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. LEGAL
& REGULATORY OUTLOOK
2.7. PATENT
OUTLOOK
2.8. FUNDING
OUTLOOK
2.9. KEY
IMPACT ANALYSIS
2.9.1. COST
2.9.2. ACCURACY
2.9.3. EASY
TO USE
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& PARTNERSHIPS
2.10.4. BUSINESS
EXPANSIONS & DIVESTITURES
2.11. MARKET
DRIVERS
2.11.1. GROWING
LIFESTYLE-ORIENTED DISEASES
2.11.2. SURGING
PREVALENCE OF GENETIC DISEASES
2.12. MARKET
CHALLENGES
2.12.1. GROWING
ETHICAL ISSUES REGARDING TECHNOLOGY USE
2.12.2. LIKELY
MISUSE OF GENE-EDITING TOOL
2.13. MARKET
OPPORTUNITIES
2.13.1. ADVANCEMENTS
IN GENE-BASED THERAPY IN THE AGRICULTURAL SECTOR
2.13.2. INCREASED
NEED FOR CLINICAL TRIALS
2.13.3. RISE
IN AWARENESS ABOUT GENE THERAPEUTICS
3. EUROPE
CRISPR MARKET OUTLOOK - BY PRODUCT
3.1. PLASMIDS
3.2. VECTORS
3.3. PROTEINS
3.4. DESIGNING
TOOLS
3.5. GRNA
3.6. CONTROL
KITS
3.7. LIBRARY
3.8. OTHER
PRODUCTS
4. EUROPE
CRISPR MARKET OUTLOOK - BY APPLICATION
4.1. GENOME
EDITING/GENETIC ENGINEERING
4.2. CRISPR
PLASMID
4.3. HUMAN
STEM CELLS
4.4. GRNA
DATABASE/GENE LIBRARY
4.5. CELL
LINE ENGINEERING
5. EUROPE
CRISPR MARKET OUTLOOK - BY INDUSTRY VERTICALS
5.1. THERAPEUTICS
AND DRUG DISCOVERY
5.2. BIOLOGICAL
RESEARCH
5.3. AGRICULTURAL
BIOTECH
5.4. INDUSTRIAL
BIOTECH
6. EUROPE
CRISPR MARKET – REGIONAL OUTLOOK
6.1. UNITED
KINGDOM
6.2. GERMANY
6.3. FRANCE
6.4. SPAIN
6.5. ITALY
6.6. RUSSIA
6.7. REST
OF EUROPE
7. COMPETITIVE
LANDSCAPE
7.1. ADDGENE
7.2. CARIBOU
BIOSCIENCES INC
7.3. CELLECTIS
BIORESEARCH SAS
7.4. CRISPR
THERAPEUTICS AG
7.5. EDITAS
MEDICINE
7.6. GENSCRIPT
7.7. HORIZON
DISCOVERY GROUP
7.8. INTEGRATED
DNA TECHNOLOGIES
7.9. INTELLIA
THERAPEUTICS
7.10. LONZA
GROUP LTD
7.11. NEW
ENGLAND BIOLABS
7.12. NOVARTIS
INTERNATIONAL AG
7.13. ORIGENE
TECHNOLOGIES INC
7.14. PRECISION
BIOSCIENCES
7.15. SYNTHEGO
CORPORATION
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.2. SOURCES
OF DATA
8.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE CRISPR MARKET,
BY COUNTRY, 2021-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: REGULATORY FRAMEWORK
TABLE 4: FUNDING OUTLOOK OF
PUBLIC COMPANIES
TABLE 5: FUNDING OUTLOOK OF
PRIVATE COMPANIES
TABLE 6: FUNDING OUTLOOK OF
GOVERNMENT ORGANIZATIONS
TABLE 7: EUROPE CRISPR MARKET,
BY PRODUCT, 2021-2028 (IN $ MILLION)
TABLE 8: EUROPE CRISPR MARKET,
BY APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 9: EUROPE CRISPR MARKET,
BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 10: EUROPE CRISPR
MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: FUNDING SCENARIO
SHARE, BY TYPE OF COMPANIES/ORGANIZATION
FIGURE 3: KEY IMPACT ANALYSIS
FIGURE 4: EUROPE CRISPR
MARKET, BY PRODUCT, 2020 & 2028 (IN %)
FIGURE 5: EUROPE CRISPR
MARKET, BY PLASMIDS, 2021-2028 (IN $ MILLION)
FIGURE 6: EUROPE CRISPR
MARKET, BY VECTORS, 2021-2028 (IN $ MILLION)
FIGURE 7: EUROPE CRISPR
MARKET, BY PROTEINS, 2021-2028 (IN $ MILLION)
FIGURE 8: EUROPE CRISPR
MARKET, BY DESIGNING TOOLS, 2021-2028 (IN $ MILLION)
FIGURE 9: EUROPE CRISPR
MARKET, BY GRNA, 2021-2028 (IN $ MILLION)
FIGURE 10: EUROPE CRISPR
MARKET, BY CONTROL KITS, 2021-2028 (IN $ MILLION)
FIGURE 11: EUROPE CRISPR
MARKET, BY LIBRARY, 2021-2028 (IN $ MILLION)
FIGURE 12: EUROPE CRISPR
MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
FIGURE 13: EUROPE CRISPR
MARKET, BY APPLICATION, 2020 & 2028 (IN %)
FIGURE 14: EUROPE CRISPR
MARKET, BY GENOME EDITING/GENETIC ENGINEERING, 2021-2028 (IN $ MILLION)
FIGURE 15: EUROPE CRISPR
MARKET, BY CRISPR PLASMID, 2021-2028 (IN $ MILLION)
FIGURE 16: EUROPE CRISPR
MARKET, BY HUMAN STEM CELLS, 2021-2028 (IN $ MILLION)
FIGURE 17: EUROPE CRISPR
MARKET, BY GRNA DATABASE/GENE LIBRARY, 2021-2028 (IN $ MILLION)
FIGURE 18: EUROPE CRISPR
MARKET, BY CELL LINE ENGINEERING, 2021-2028 (IN $ MILLION)
FIGURE 19: EUROPE CRISPR
MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 20: EUROPE CRISPR
MARKET, BY THERAPEUTICS AND DRUG DISCOVERY, 2021-2028 (IN $ MILLION)
FIGURE 21: EUROPE CRISPR
MARKET, BY BIOLOGICAL RESEARCH, 2021-2028 (IN $ MILLION)
FIGURE 22: EUROPE CRISPR
MARKET, BY AGRICULTURAL BIOTECH, 2021-2028 (IN $ MILLION)
FIGURE 23: EUROPE CRISPR
MARKET, BY INDUSTRIAL BIOTECH, 2021-2028 (IN $ MILLION)
FIGURE 24: EUROPE CRISPR
MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
FIGURE 25: UNITED KINGDOM
CRISPR MARKET 2021-2028 (IN $ MILLION)
FIGURE 26: GERMANY CRISPR
MARKET 2021-2028 (IN $ MILLION)
FIGURE 27: FRANCE CRISPR
MARKET 2021-2028 (IN $ MILLION)
FIGURE 28: SPAIN CRISPR MARKET
2021-2028 (IN $ MILLION)
FIGURE 29: ITALY CRISPR MARKET
2021-2028 (IN $ MILLION)
FIGURE 30: RUSSIA CRISPR
MARKET 2021-2028 (IN $ MILLION)
FIGURE 31: REST OF EUROPE
CRISPR MARKET 2021-2028 (IN $ MILLION)